This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Alkan G, Senturk Oztas N, Turna ZH, Ozguroglu M. 1168P Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. Ann Oncol. 2022; 33:S1082. https://doi.org/10.1016/j.annonc.2022.07.1291AlkanGSenturk OztasNTurnaZHOzgurogluM.1168P Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer..2022;33:S1082. https://doi.org/10.1016/j.annonc.2022.07.1291Open DOISearch in Google Scholar
American Cancer Society. What causes lung cancer? [Internet]. Atlanta (USA): American Cancer Society, Inc.; 2019 [cited 2023 May 5]. Available from https://www.cancer.org/cancer/lung-cancer/causes-risks-prevention/what-causes.htmlAmerican Cancer Society..Atlanta (USA):American Cancer Society, Inc.;2019[cited 2023 May 5].Available from https://www.cancer.org/cancer/lung-cancer/causes-risks-prevention/what-causes.htmlSearch in Google Scholar
Brawley OW, Glynn TJ, Khuri FR, Wender RC, Seffrin JR. The first Surgeon General’s report on smoking and health: the 50th anniversary. CA Cancer J Clin. 2014 Jan–Feb;64(1):5–8. https://doi.org/10.3322/caac.21210BrawleyOWGlynnTJKhuriFRWenderRCSeffrinJR.The first Surgeon General’s report on smoking and health: the 50th anniversary..2014Jan–Feb;64(1):5–8. https://doi.org/10.3322/caac.21210Open DOISearch in Google Scholar
Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 Dec;358(6369):1443–1448. https://doi.org/10.1126/science.aal5240BullmanSPedamalluCSSicinskaEClancyTEZhangXCaiDNeubergDHuangKGuevaraFNelsonT.Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer..2017Dec;358(6369):1443–1448. https://doi.org/10.1126/science.aal5240Open DOISearch in Google Scholar
CDC. What are the risk factors for lung cancer? [Internet]. Atlanta (USA): Centers for Disease Control and Prevention; 2023 [cited 2023 May 5]. Available from https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htmCDC..Atlanta (USA):Centers for Disease Control and Prevention;2023[cited 2023 May 5].Available from https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htmSearch in Google Scholar
Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG; im CORE working group of early career investigators. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020 Apr;31(4):525–531. https://doi.org/10.1016/j.annonc.2020.01.006ChalabiMCardonaANagarkarDRDhawahir ScalaAGandaraDRRittmeyerAAlbertMLPowlesTKokMHerreraFGim CORE working group of early career investigators.Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials..2020Apr;31(4):525–531. https://doi.org/10.1016/j.annonc.2020.01.006Open DOISearch in Google Scholar
Chang ET, Smedby KE, Hjalgrim H, Schöllkopf C, Porwit-Mac-Donald A, Sundström C, Tani E, d’Amore F, Melbye M, Adami HO, et al. Medication use and risk of non-Hodgkin’s lymphoma. Am J Epidemiol. 2005 Nov;162(10):965–974. https://doi.org/10.1093/aje/kwi311ChangETSmedbyKEHjalgrimHSchöllkopfCPorwit-Mac-DonaldASundströmCTaniEd’AmoreFMelbyeMAdamiHO.Medication use and risk of non-Hodgkin’s lymphoma..2005Nov;162(10):965–974. https://doi.org/10.1093/aje/kwi311Open DOISearch in Google Scholar
Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and nonsmall-cell lung cancer. Ann Oncol. 2018 Jun;29(6):1437–1444. https://doi.org/10.1093/annonc/mdy103DerosaLHellmannMDSpazianoMHalpennyDFidelleMRizviHLongNPlodkowskiAJArbourKCChaftJE.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and nonsmall-cell lung cancer..2018Jun;29(6):1437–1444. https://doi.org/10.1093/annonc/mdy103Open DOISearch in Google Scholar
Dickson RP, Huffnagle GB. The lung microbiome: New principles for respiratory bacteriology in health and disease. PLoS Pathog. 2015 Jul;11(7):e1004923. https://doi.org/10.1371/journal.ppat.1004923DicksonRPHuffnagleGB.The lung microbiome: New principles for respiratory bacteriology in health and disease..2015Jul;11(7):e1004923. https://doi.org/10.1371/journal.ppat.1004923Open DOISearch in Google Scholar
Didham RC, Reith DM, McConnell DW, Harrison KS. Antibiotic exposure and breast cancer in New Zealand. Breast Cancer Res Treat. 2005 Jul;92(2):163–167. https://doi.org/10.1007/s10549-005-2115-8DidhamRCReithDMMcConnellDWHarrisonKS.Antibiotic exposure and breast cancer in New Zealand..2005Jul;92(2):163–167. https://doi.org/10.1007/s10549-005-2115-8Open DOISearch in Google Scholar
ECIS. European Cancer Information System. Brussels (Belgium): European Union; 2023 [cited 2023 May 5]. Available from https://ecis.jrc.ec.europa.euECIS..Brussels (Belgium):European Union;2023[cited 2023 May 5].Available from https://ecis.jrc.ec.europa.euSearch in Google Scholar
Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: A new independent prognostic factor? Ann Oncol. 2019 Oct;30(10):1572–1579. https://doi.org/10.1093/annonc/mdz206ElkriefADerosaLKroemerGZitvogelLRoutyB.The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: A new independent prognostic factor?.2019Oct;30(10):1572–1579. https://doi.org/10.1093/annonc/mdz206Open DOISearch in Google Scholar
Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment – a nationwide populationbased study. Cancer Manag Res. 2019 Sep;11:8539–8546. https://doi.org/10.2147/CMAR.S222278FangYHYangYHHsiehMJHungMSLinYC.Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment – a nationwide populationbased study..2019Sep;11:8539–8546. https://doi.org/10.2147/CMAR.S222278Open DOISearch in Google Scholar
Galli G, Poggi M, Fucà G, Imbimbo M, Proto C, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F, et al. Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer. Ann Oncol. 2018 Nov;29:viii531. https://doi.org/10.1093/annonc/mdy292.088GalliGPoggiMFucàGImbimboMProtoCSignorelliDVitaliMZilemboNGanzinelliMde BraudF.Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer..2018Nov;29:viii531. https://doi.org/10.1093/annonc/mdy292.088Open DOISearch in Google Scholar
Geum MJ, Kim C, Kang JE, Choi JH, Kim JS, Son ES, Lim SM, Rhie SJ. Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer. Pharmaceuticals. 2021 May;14(5):445. https://doi.org/10.3390/ph14050445GeumMJKimCKangJEChoiJHKimJSSonESLimSMRhieSJ.Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer..2021May;14(5):445. https://doi.org/10.3390/ph14050445Open DOISearch in Google Scholar
Gonugunta AS, Von Itzstein MS, Hsiehchen D, Le T, Rashdan S, Yang H, Selby C, Alvarez C, Gerber DE. Antibiotic prescriptions in lung cancer and melanoma populations: Differences with potential clinical implications in the immunotherapy era. Clin Lung Cancer. 2023 Jan;24(1):11–17. https://doi.org/10.1016/j.cllc.2022.09.005GonuguntaASVon ItzsteinMSHsiehchenDLeTRashdanSYangHSelbyCAlvarezCGerberDE.Antibiotic prescriptions in lung cancer and melanoma populations: Differences with potential clinical implications in the immunotherapy era..2023Jan;24(1):11–17. https://doi.org/10.1016/j.cllc.2022.09.005Open DOISearch in Google Scholar
Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018 Apr;33(4):570–580. https://doi.org/10.1016/j.ccell.2018.03.015GopalakrishnanVHelminkBASpencerCNReubenAWargoJA.The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy..2018Apr;33(4):570–580. https://doi.org/10.1016/j.ccell.2018.03.015Open DOISearch in Google Scholar
Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007 May;1(1):56–66. https://doi.org/10.1038/ismej.2007.3JernbergCLöfmarkSEdlundCJanssonJK.Long-term ecological impacts of antibiotic administration on the human intestinal microbiota..2007May;1(1):56–66. https://doi.org/10.1038/ismej.2007.3Open DOISearch in Google Scholar
Kilkkinen A, Rissanen H, Klaukka T, Pukkala E, Heliövaara M, Huovinen P, Männistö S, Aromaa A, Knekt P. Antibiotic use predicts an increased risk of cancer. Int J Cancer. 2008 Nov;123(9): 2152–2155. https://doi.org/10.1002/ijc.23622KilkkinenARissanenHKlaukkaTPukkalaEHeliövaaraMHuovinenPMännistöSAromaaAKnektP.Antibiotic use predicts an increased risk of cancer..2008Nov;123(9):2152–2155. https://doi.org/10.1002/ijc.23622Open DOISearch in Google Scholar
Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez--Outschoorn UE, Sotgia F, Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget. 2015 Mar;6(7):4569–4584. https://doi.org/10.18632/oncotarget.3174LambROzsvariBLisantiCLTanowitzHBHowellAMartinez--OutschoornUESotgiaFLisantiMP.Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease..2015Mar;6(7):4569–4584. https://doi.org/10.18632/oncotarget.3174Open DOISearch in Google Scholar
Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, et al. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: A strategy to promote immunosurveillance against lung metastases. Cell Rep. 2018 Sep;24(13):3528–3538. https://doi.org/10.1016/j.celrep.2018.08.090Le NociVGuglielmettiSArioliSCamisaschiCBianchiFSommarivaMStortiCTriulziTCastelliCBalsariA.Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: A strategy to promote immunosurveillance against lung metastases..2018Sep;24(13):3528–3538. https://doi.org/10.1016/j.celrep.2018.08.090Open DOISearch in Google Scholar
Lee SH, Sung JY, Yong D, Chun J, Kim SY, Song JH, Chung KS, Kim EY, Jung JY, Kang YA, et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer. 2016 Dec;102:89–95. https://doi.org/10.1016/j.lungcan.2016.10.016LeeSHSungJYYongDChunJKimSYSongJHChungKSKimEYJungJYKangYA.Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions..2016Dec;102:89–95. https://doi.org/10.1016/j.lungcan.2016.10.016Open DOISearch in Google Scholar
Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM, Qu JM. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int J Cancer. 2018 Feb; 142(4):769–778. https://doi.org/10.1002/ijc.31098LiuHXTaoLLZhangJZhuYGZhengYLiuDZhouMKeHShiMMQuJM.Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects..2018Feb;142(4):769–778. https://doi.org/10.1002/ijc.31098Open DOISearch in Google Scholar
Löfling L, Bahmanyar S, Kieler H, Lambe M, Wagenius G. Anti-biotic use prior to a lung cancer diagnosis: A population-based study. Cancer Causes Control. 2021 Jun;32(6):597–607. https://doi.org/10.1007/s10552-021-01413-5LöflingLBahmanyarSKielerHLambeMWageniusG.Anti-biotic use prior to a lung cancer diagnosis: A population-based study..2021Jun;32(6):597–607. https://doi.org/10.1007/s10552-021-01413-5Open DOISearch in Google Scholar
Löfmark S, Jernberg C, Jansson JK, Edlund C. Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes. J Antimicrob Chemother. 2006 Dec; 58(6): 1160–1167. https://doi.org/10.1093/jac/dkl420LöfmarkSJernbergCJanssonJKEdlundC.Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes..2006Dec;58(6):1160–1167. https://doi.org/10.1093/jac/dkl420Open DOISearch in Google Scholar
Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012 Sep;489(7415):220–230. https://doi.org/10.1038/nature11550LozuponeCAStombaughJIGordonJIJanssonJKKnightR.Diversity, stability and resilience of the human gut microbiota..2012Sep;489(7415):220–230. https://doi.org/10.1038/nature11550Open DOISearch in Google Scholar
Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, Buffet R, Bandinelli PA. NSCLC immunotherapy efficacy and antibiotic use: A systematic review and meta-analysis. J Thorac Oncol. 2020 Jul;15(7):1147–1159. https://doi.org/10.1016/j.jtho.2020.03.002LurienneLCervesiJDuhaldeLde GunzburgJAndremontAZalcmanGBuffetRBandinelliPA.NSCLC immunotherapy efficacy and antibiotic use: A systematic review and meta-analysis..2020Jul;15(7):1147–1159. https://doi.org/10.1016/j.jtho.2020.03.002Open DOISearch in Google Scholar
Majeed U, Zhou K, Heng F, Seegobin K, Zhao Y, Manochakian R, Lou Y. P13.01 Use of antibiotics is associated with an increase in immunotherapy related adverse effects in patients with non-small cell lung cancer. J Thorac Oncol. 2021 Oct;16(10):S1010. https://doi.org/10.1016/j.jtho.2021.08.330MajeedUZhouKHengFSeegobinKZhaoYManochakianRLouY.P13.01 Use of antibiotics is associated with an increase in immunotherapy related adverse effects in patients with non-small cell lung cancer..2021Oct;16(10):S1010. https://doi.org/10.1016/j.jtho.2021.08.330Open DOISearch in Google Scholar
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 Jan; 359(6371):104–108. https://doi.org/10.1126/science.aao3290MatsonVFesslerJBaoRChongsuwatTZhaYAlegreMLLukeJJGajewskiTF.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients..2018Jan;359(6371):104–108. https://doi.org/10.1126/science.aao3290Open DOISearch in Google Scholar
Mayo Clinic. Antibiotics: Are you misusing them? [Internet]. Rochester (USA): Mayo Foundation for Medical Education and Research; 2023 [cited 2023 May 5]. Available from https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/antibiotics/art-20045720Mayo Clinic..Rochester (USA):Mayo Foundation for Medical Education and Research;2023[cited 2023 May 5].Available from https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/antibiotics/art-20045720Search in Google Scholar
Nyein AF, Bari S, Hogue S, Zhao Y, Maller B, Sha S, Gomez MF, Rollison DE, Robinson LA. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. BMC Cancer. 2022 Jan ;22(1):101. https://doi.org/10.1186/s12885-022-09210-2NyeinAFBariSHogueSZhaoYMallerBShaSGomezMFRollisonDERobinsonLA.Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer..2022Jan;22(1):101. https://doi.org/10.1186/s12885-022-09210-2Open DOISearch in Google Scholar
Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer. 2021 May;149:73–81. https://doi.org/10.1016/j.ejca.2021.02.040OchiNIchiharaETakigawaNHaradaDInoueKShibayamaTHosokawaSKishinoDHaritaSOdaN.The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression..2021May;149:73–81. https://doi.org/10.1016/j.ejca.2021.02.040Open DOISearch in Google Scholar
Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, Hansen TH, Liang S, Feng Q, Zhang C, et al Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018 Nov;3(11):1255–1265. https://doi.org/10.1038/s41564-018-0257-9PallejaAMikkelsenKHForslundSKKashaniAAllinKHNielsenTHansenTHLiangSFengQZhangCRecovery of gut microbiota of healthy adults following antibiotic exposure..2018Nov;3(11):1255–1265. https://doi.org/10.1038/s41564-018-0257-9Open DOISearch in Google Scholar
Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Oggionni E, Abeni C, Hahne JC, Tomasello G, et al. Use of antibiotics and risk of cancer: A systematic review and meta-analysis of observational studies. Cancers. 2019 Aug;11(8):1174. https://doi.org/10.3390/cancers11081174PetrelliFGhidiniMGhidiniAPeregoGCabidduMKhakooSOggionniEAbeniCHahneJCTomaselloG.Use of antibiotics and risk of cancer: A systematic review and meta-analysis of observational studies..2019Aug;11(8):1174. https://doi.org/10.3390/cancers11081174Open DOISearch in Google Scholar
Pierrard J, Seront E. Impact of the gut microbiome on immune checkpoint inhibitor efficacy – a systematic review. Curr Oncol. 2019 Dec;26(6):395–403. https://doi.org/10.3747/co.26.5177PierrardJSerontE.Impact of the gut microbiome on immune checkpoint inhibitor efficacy – a systematic review..2019Dec;26(6):395–403. https://doi.org/10.3747/co.26.5177Open DOISearch in Google Scholar
Ramírez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, Gálvez EM. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy. Trends Cancer. 2020 Feb;6(2): 86–97. https://doi.org/10.1016/j.trecan.2019.12.007Ramírez-LabradaAGIslaDArtalAAriasMRezustaAPardoJGálvezEM.The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy..2020Feb;6(2):86–97. https://doi.org/10.1016/j.trecan.2019.12.007Open DOISearch in Google Scholar
Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Rang and Dale’s pharmacology, 9th ed. Edinburgh (UK): Elsevier. p. 673.RitterJMFlowerRHendersonGLokeYKMacEwanDRangHP.,9th ed.Edinburgh (UK):Elsevier. p.673.Search in Google Scholar
Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Montagna ES, Ungaro V, Lorusso M, Palmiotti G. Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: A systematic review and meta-analysis. Cancers. 2022 Mar;14(6):1404. https://doi.org/10.3390/cancers14061404RizzoACusmaiAGiovannelliFAcquafreddaSRinaldiLMisinoAMontagnaESUngaroVLorussoMPalmiottiG.Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: A systematic review and meta-analysis..2022Mar;14(6):1404. https://doi.org/10.3390/cancers14061404Open DOISearch in Google Scholar
Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018b Jun;15(6): 382–396. https://doi.org/10.1038/S41571-018-0006-2RoutyBGopalakrishnanVDaillèreRZitvogelLWargoJAKroemerG.The gut microbiota influences anticancer immunosurveillance and general health..2018bJun;15(6):382–396. https://doi.org/10.1038/S41571-018-0006-2Open DOISearch in Google Scholar
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018a Jan;359(6371):91–97. https://doi.org/10.1126/science.aan3706RoutyBLe ChatelierEDerosaLDuongCPMAlouMTDaillèreRFluckigerAMessaoudeneMRauberCRobertiMP.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors..2018aJan;359(6371):91–97. https://doi.org/10.1126/science.aan3706Open DOISearch in Google Scholar
Ruiz-Patiño A, Barrón F, Cardona AF, Corrales L, Mas L, Martín C, Zatarain-Barrón ZL, Recondo G, Ricaurte L, Rojas L, et al.; CLICaP. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP). Thorac Cancer. 2020 Sep;11(9):2552–2560. https://doi.org/10.1111/1759-7714.13573Ruiz-PatiñoABarrónFCardonaAFCorralesLMasLMartínCZatarain-BarrónZLRecondoGRicaurteLRojasL.;CLICaP. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP)..2020Sep;11(9):2552–2560. https://doi.org/10.1111/1759-7714.13573Open DOISearch in Google Scholar
Santacroce L, Charitos IA, Ballini A, Inchingolo F, Luperto P, De Nitto E, Topi S. The Human respiratory system and its microbiome at a glimpse. Biology. 2020 Oct;9(10):318. https://doi.org/10.3390/biology9100318SantacroceLCharitosIABalliniAInchingoloFLupertoPDe NittoETopiS.The Human respiratory system and its microbiome at a glimpse..2020Oct;9(10):318. https://doi.org/10.3390/biology9100318Open DOISearch in Google Scholar
Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer. Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1563–1579. https://doi.org/10.1158/1055-9965.EPI-19-0221SchabathMBCoteML.Cancer progress and priorities: Lung cancer..2019Oct;28(10):1563–1579. https://doi.org/10.1158/1055-9965.EPI-19-0221Open DOISearch in Google Scholar
Schett A, Rothschild SI, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol. 2020 Jan;85(1):121–131. https://doi.org/10.1007/s00280-019-03993-1SchettARothschildSICurioni-FontecedroAKrähenbühlSFrühMSchmidSDriessenCJoergerM.Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: Antibiotics immune checkpoint inhibitors in advanced NSCLC..2020Jan;85(1):121–131. https://doi.org/10.1007/s00280-019-03993-1Open DOISearch in Google Scholar
Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, Kurata S. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int. 2003 Feb; 45(1): 86–90. https://doi.org/10.1046/j.1442-200X.2003.01671.xSekiHShioharaMMatsumuraTMiyagawaNTanakaMKomiyamaAKurataS.Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI..2003Feb;45(1):86–90. https://doi.org/10.1046/j.1442-200X.2003.01671.xOpen DOISearch in Google Scholar
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov;350(6264):1084–1089. https://doi.org/10.1126/science.aac4255SivanACorralesLHubertNWilliamsJBAquino-MichaelsKEarleyZMBenyaminFWLeiYMJabriBAlegreML.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy..2015Nov;350(6264):1084–1089. https://doi.org/10.1126/science.aac4255Open DOISearch in Google Scholar
Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001 Sep; 1(2):101–114. https://doi.org/10.1016/S1473-3099(01)00066-4SullivanAEdlundCNordCE.Effect of antimicrobial agents on the ecological balance of human microflora..2001Sep;1(2):101–114. https://doi.org/10.1016/S1473-3099(01)00066-4Open DOISearch in Google Scholar
Thomas S. Antimicrobial resistance: Global challenges and future interventions. Singapore: Springer Singapore; 2020. https://doi.org/10.1007/978-981-15-3658-8ThomasS..Singapore:Springer Singapore;2020. https://doi.org/10.1007/978-981-15-3658-8Open DOISearch in Google Scholar
Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, Jodai T, Akaike K, Ishizuka S, Saeki S, et al. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol Res. 2020 Oct;8(10):1236–1242. https://doi.org/10.1158/2326-6066.CIR-20-0051TomitaYIkedaTSakataSSaruwatariKSatoRIyamaSJodaiTAkaikeKIshizukaSSaekiS.Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer..2020Oct;8(10):1236–1242. https://doi.org/10.1158/2326-6066.CIR-20-0051Open DOISearch in Google Scholar
Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. JAMA. 2004 Feb;291(7):827–835. https://doi.org/10.1001/jama.291.7.827VelicerCMHeckbertSRLampeJWPotterJDRobertsonCATaplinSH.Antibiotic use in relation to the risk of breast cancer..2004Feb;291(7):827–835. https://doi.org/10.1001/jama.291.7.827Open DOISearch in Google Scholar
Weinberger SE, Cockrill BA, Mandel J. 20 – Lung cancer: Etiologic and pathologic aspects. In: Principles of pulmonary medicine, 7th ed. Philadelphia (USA): Elsevier; 2019. p. 263. https://doi.org/10.1016/B978-0-323-52371-4.00023-4WeinbergerSECockrillBAMandelJ.20 – Lung cancer: Etiologic and pathologic aspects. In:,7th ed.Philadelphia (USA):Elsevier;2019. p.263. https://doi.org/10.1016/B978-0-323-52371-4.00023-4Open DOISearch in Google Scholar
WHO. Antibiotic resistance [Internet]. Geneva (Switzerland): World Health Organization; 2023 [cited 2023 April 30]. Available from https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistanceWHO..Geneva (Switzerland):World Health Organization;2023[cited 2023 April 30].Available from https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistanceSearch in Google Scholar
Wu X, Li F, Wang X, Li C, Meng Q, Wang C, Huang J, Chen S, Zhu Z. Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism. Biochem Biophys Res Commun. 2018 Jan;495(1):267–272. https://doi.org/10.1016/j.bbrc.2017.10.136WuXLiFWangXLiCMengQWangCHuangJChenSZhuZ.Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism..2018Jan;495(1):267–272. https://doi.org/10.1016/j.bbrc.2017.10.136Open DOISearch in Google Scholar
You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006 Jul;98(14):974–983. https://doi.org/10.1093/jnci/djj264YouWCBrownLMZhangLLiJYJinMLChangYSMaJLPanKFLiuWDHuY.Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions..2006Jul;98(14):974–983. https://doi.org/10.1093/jnci/djj264Open DOISearch in Google Scholar
Zhang H, García Rodríguez LA, Hernández-Díaz S. Antibiotic use and the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1308–1315. https://doi.org/10.1158/1055-9965.EPI-07-2817ZhangHGarcía RodríguezLAHernández-DíazS.Antibiotic use and the risk of lung cancer..2008Jun;17(6):1308–1315. https://doi.org/10.1158/1055-9965.EPI-07-2817Open DOISearch in Google Scholar
Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell. 2016 Apr;165(2):276–287. https://doi.org/10.1016/j.cell.2016.03.001ZitvogelLAyyoubMRoutyBKroemerG.Microbiome and anticancer immunosurveillance..2016Apr;165(2):276–287. https://doi.org/10.1016/j.cell.2016.03.001Open DOISearch in Google Scholar